Skip to main content
SpringerLink
Log in

Eplerenone reduces deaths from heart failure after a heart attack and effectively treats hypertension

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104: el4–8

    Article  Google Scholar 

  2. Keating GM, Plosker GL. Eplerenone: a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. Drugs 2004; 64(23): 2689–707

    Article  PubMed  CAS  Google Scholar 

  3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004 Aug 4; 44(3): 671–719

    Article  PubMed  Google Scholar 

  4. Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 2005; 5(1): 51–69

    Article  PubMed  CAS  Google Scholar 

  5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldos-terone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3; 348(14): 1309–21

    Article  PubMed  CAS  Google Scholar 

  6. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infaraction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46(3): 425–31

    Article  PubMed  CAS  Google Scholar 

  7. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005 Mar 8; 111(9): 1106–13

    Article  PubMed  Google Scholar 

  8. Kvasz M, Zhang Z, Lenz C, et al. Cost-effectiveness evaluation of eplerenone in patients with heart failure following AMI in Germany [abstract no. PCV13]. Value Health 2005 May–Jun; 8(3): 264

    Article  Google Scholar 

  9. Weintraub WS, Zhang Z, Kvasz M, et al. Cost-effectiveness of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction: results from EPHESUS [abstract no. P-2299]. Annual Congress of the European Society of Cardiology; 2005 Sep 3–7; Stockholm

  10. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002 Aug; 15(8): 709–16

    Article  PubMed  CAS  Google Scholar 

  11. White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003 Jul 1; 92(1): 38–42

    Article  PubMed  CAS  Google Scholar 

  12. Saruta T, Kageyama S, Ogihara T, et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich) 2004 Apr; 6(4): 175–85

    Article  CAS  Google Scholar 

  13. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002 Aug; 40(2): 117–23

    Article  PubMed  CAS  Google Scholar 

  14. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93(8): 990–6

    Article  PubMed  CAS  Google Scholar 

  15. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003 Apr 2; 41(7): 1148–55

    Article  PubMed  CAS  Google Scholar 

  16. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003 May; 41: 1021–6

    Article  PubMed  CAS  Google Scholar 

  17. G.D. Searle LLC. Inspra (eplerenone) tablets: prescribing information. New York, 2005 May

  18. Pfizer Limited. Inspra 25mg and 50mg film-coated tablets: summary of product characteristics. Sandwich, UK, 2004 Sep

  19. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 Jun; 26(11): 1115–40

    Article  PubMed  Google Scholar 

  20. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994 Apr; 50: 272–98

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eplerenone reduces deaths from heart failure after a heart attack and effectively treats hypertension. Drugs Ther. Perspect 22, 1–4 (2006). https://doi.org/10.2165/00042310-200622010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622010-00001

Search

Navigation